Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "9525", "attributes": { "award_id": "6U48DP006401-03M001", "title": "Connecting Behavioral Science to COVID-19 Vaccine Demand (CBS-CVD) Network", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2024-09-29", "award_amount": 397000, "principal_investigator": { "id": 25231, "first_name": "SARA", "last_name": "WILCOX", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "9527", "attributes": { "award_id": "75N93019C00065-P00006-9999-2", "title": "LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2021-09-29", "award_amount": 299928, "principal_investigator": { "id": 25233, "first_name": "STEPHEN", "last_name": "WILSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 epitope Megapools (SARS-CoV-2 MPs) is used to study SARS-CoV-2 CD4 and CD8 specific T cell responses. The Megapool (MP) approach allows simultaneous testing of large number of epitopes. According to this approach large numbers of different epitopes are solubilized, pooled and re-lyophilized to avoid cell toxicity problems associated with high concentrations of DMSO typically encountered when single pre-solubilized epitopes are pooled. These MPs have been used for both CD4 and CD8 T cell epitope identification.", "keywords": [ "2019-nCoV", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "Cells", "Contracts", "Coronavirus", "Dimethyl Sulfoxide", "Epitopes", "Freeze Drying", "Ships", "T cell response", "T-Lymphocyte Epitopes", "Testing", "Toxic effect", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9530", "attributes": { "award_id": "6U48DP006397-02M002", "title": "Prevention Research Center of Michigan: COVID Vaccine Confidence Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2024-09-29", "award_amount": 500000, "principal_investigator": { "id": 25237, "first_name": "Marc A", "last_name": "Zimmerman", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "9531", "attributes": { "award_id": "75N93019C00062-P00003-9999-2", "title": "COVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-16", "end_date": "2022-03-15", "award_amount": 1810144, "principal_investigator": { "id": 25238, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the identification of human B cell epitopes derived from viral pathogens; such as Coronavirus, Dengue virus 4, Powassan virus, Chikungunya virus, and Venezuelan equine encephalitis virus, combined with basic studies to understand protective immunity mediated by antibodies, as well as pathological consequences of antibody responses.", "keywords": [ "Antibodies", "Antibody Response", "Antibody-mediated protection", "B-Lymphocyte Epitopes", "Chikungunya virus", "Coronavirus", "Dengue Virus", "Human", "Pathologic", "Powassan virus", "Support Contracts", "Venezuelan Equine Encephalitis Virus", "coronavirus disease", "pathogenic virus" ], "approved": true } }, { "type": "Grant", "id": "9536", "attributes": { "award_id": "2030139", "title": "Compounding Crises: Facing Hurricane Season in the Era of COVID-19", "funder": null, "funder_divisions": [], "program_reference_codes": [ "CK090", "RND123" ], "program_officials": [], "start_date": null, "end_date": null, "award_amount": 199890, "principal_investigator": null, "other_investigators": [], "awardee_organization": null, "abstract": "Test", "keywords": [ "covid", "research" ], "approved": true } }, { "type": "Grant", "id": "9663", "attributes": { "award_id": "1IK6CX002519-01", "title": "CSRD Research Career Scientist Award Application", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-04-01", "end_date": "2029-03-31", "award_amount": null, "principal_investigator": { "id": 22671, "first_name": "Judith M", "last_name": "Ford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1522, "ror": "", "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1522, "ror": "", "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Dr. Ford is an established investigator in neuroscience and psychiatry, with a PhD in neuroscience and life-long appointments in mental health/psychiatry. She uses electroencephalography (EEG) and functional magnetic resonance imaging (fMRI), to investigate the neurobiology of schizophrenia (SZ) and major depressive disorder (MDD). And now, she is adding COVID19 “long haulers” to the conditions she studies with brain imaging methods. SZ. Dr. Ford’s work in SZ was focused on an elemental neural system that dampens neural responses to self- generated stimuli compared to stimuli arising from the environment. It is thought to reflect the operation of an efference copy/corollary discharge mechanism involving signaling from motor to sensory regions, preparing sensory regions for self-generated sensory events. This mechanism is ubiquitous across all animal species, and her work in translating this mechanism to a human paradigm has uncovered a fundamental deficit in sensory information processing in people on the psychosis spectrum. With NIH R01 funding, she has shown deficiencies in these mechanisms are linked to auditory hallucinations and delusions. With current NIH R03 funding, she is now asking about the role of the thalamo-pontine-cerebellar circuit in the successful operation of this system. Two of Dr. Ford’s VA trainees are now extending this work to a new sample of people with psychosis, their 1st degree relatives, youth at clinical risk for developing psychosis, and non-affected control participants. They are finding connectivity between cerebellum and pons is related to the action of the efference copy/corollary discharge mechanism. With a more recently funded NIH R03 grant, she is asking whether EEG-assessed slowed perception has upstream effects on cognition and contributes to clinical features of psychosis in the schizophrenia spectrum. With a to-be-funded mechanistic clinical trial (NIH R21) involving a VA psychiatrist, a VA radiologist, and a UCSF cardiologist, she is asking whether a ketogenic diet can restore neural network stability in SZ, thereby addressing both cognitive deficits and metabolic syndrome, associated with poor function and a shortened life span, respectively. MDD/SZ. About 4 years ago, she added MDD to the clinical populations she studies and is asking about the negative consequences of rumination and whether they can be rescued by a mindfulness approach to life. Rumination is an internal cognitive state characterized by recursive thinking of self-distress and negative events focusing on the causes and consequences of distress rather than solutions. It cuts across diagnostic boundaries: It is associated with symptom severity and chronicity in both MDD and SZ. Mindfulness is associated with less distress from auditory hallucinations in SZ and fewer residual symptoms in MDD. It involves attending to present moment experiences and sensations and allowing emotions and thoughts to enter and leave consciousness without judgment, thereby avoiding a downward spiral into rumination. Compared to simple mind wandering, mindfulness recruits an attention network including parietal and prefrontal structures while mind wandering only recruits the default mode network. Long-COVID19. The newest population she is studying is the so-called ‘long-haulers’ following COVID19 infection. While the lungs are ground zero, COVID19 tears through organ systems from brain to blood vessels. Some who recover complain of ongoing problems, including lingering cognitive problems, depression, and anxiety. Dr. Ford has joined forces with both Lab Medicine and Radiology at SFVAMC to use psychological testing, neuroimaging methods, and markers in the blood signaling damage in the brain. A close look at these problems is timely and imperative if we are to understand the pathophysiology of “COVID brain” and prepare for down-stream problems.", "keywords": [ "Address", "Advocate", "American", "Anesthesiology", "Animals", "Anxiety", "Appointment", "Asthma", "Attention", "Auditory", "Auditory Hallucination", "Award", "Behavioral Sciences", "Biological Markers", "Biological Psychiatry", "Blood", "Blood Vessels", "Brain", "Brain imaging", "COVID-19", "COVID-19 complications", "COVID-19 impact", "COVID-19 long hauler", "COVID-19 survivors", "Cerebellum", "Chronic", "Clinical", "Clinical Medicine", "Clinical Trials", "Cognition", "Cognitive", "Cognitive deficits", "Collaborations", "Congresses", "Conscious", "Delusions", "Diagnostic", "Diet", "Distress", "Doctor of Philosophy", "Educational process of instructing", "Electroencephalography", "Emotions", "Environment", "Esthesia", "Event", "Family", "First Degree Relative", "Foundations", "Functional Magnetic Resonance Imaging", "Functional disorder", "Funding", "Grant", "Group Meetings", "Hallucinations", "Human", "Hypertension", "International", "Judgment", "Ketones", "Leadership", "Learning", "Life", "Link", "Long COVID", "Longevity", "Lung", "Magnetic Resonance Imaging", "Major Depressive Disorder", "Malignant Neoplasms", "Medicine", "Mental Depression", "Mental Health", "Mentors", "Metabolic syndrome", "Methods", "Mind", "Mindfulness Training", "Morbidity - disease rate", "Motor", "Neurobiology", "Neurosciences", "Obesity", "Parietal", "Participant", "Patients", "Perception", "Persons", "Phase", "Physicians", "Pontine structure", "Population", "Psychiatrist", "Psychiatry", "Psychological Tests", "Psychologist", "Psychoses", "Radiologic Health", "Radiology Specialty", "Research", "Research Personnel", "Residual state", "Review Committee", "Role", "SARS-CoV-2 infection", "Sampling", "Schizophrenia", "Scientist", "Sensory", "Severities", "Signal Transduction", "Smoking", "Societies", "Stimulus", "Structure", "Symptoms", "System", "Talents", "Thinking", "Time", "Translating", "United States National Institutes of Health", "Veterans", "Work", "Youth", "body system", "brain behavior", "career", "clinical risk", "clinically significant", "college", "coronavirus disease", "cost", "deficit syndrome", "disability", "editorial", "experience", "high risk", "imaging modality", "imaging study", "information processing", "ketogenic diet", "long term consequences of COVID-19", "meetings", "member", "mindfulness", "mortality", "neural network", "neuroimaging", "neuropsychopharmacology", "operation", "programs", "radiologist", "recruit", "rela" ], "approved": true } }, { "type": "Grant", "id": "9664", "attributes": { "award_id": "1I50HX003637-01", "title": "Evidence-based Policy Impact Center (EPIC) QUERI", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-04-01", "end_date": "2027-03-31", "award_amount": null, "principal_investigator": { "id": 25483, "first_name": "Anashua RANI", "last_name": "Elwy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25484, "first_name": "ALLEN L", "last_name": "GIFFORD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25485, "first_name": "Sara J", "last_name": "Landes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1521, "ror": "", "name": "VA BOSTON HEALTH CARE SYSTEM", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evidence-based Policy Impact Center (EPIC) QUERI, consisting of experienced QUERI Program, Partnered Implementation Initiative, Partnered Evaluation Initiative, Rapid Response Team, and HSR&D COIN and CORE leaders, is poised to address a number of wide-ranging VA policy and evaluation priorities in response to the Foundations for Evidence-based Policymaking Act of 2018 (Evidence Act). Our proposal identifies four priority subject matter areas and two evaluation priorities for immediate attention: 1) suicide prevention initiatives for Veterans and transitioning servicemembers, and 2) effectiveness and implementation of programs to eliminate homelessness among Veterans. Since 2019, VA has taken numerous steps to become a High Reliability Organization (HRO). However, it is not yet clear whether the programs implemented across the VA to address suicide prevention and homelessness, among other priority areas, include HRO principles, such as sensitivity to operations, appreciating the complexity of healthcare, looking for opportunities for improvement, valuing insights from experts, and practicing resilience. Building on Learning Health System competencies of scientific evidence standards, methods, informatics, improvement and implementation science, and engagement with leadership, EPIC QUERI has developed robust evaluation plans to immediately examine national suicide prevention and homelessness initiatives. In addition to strengths in operations, methods, and knowledge translation, EPIC QUERI brings a unique perspective to the Evidence Act by creating 1) a workforce development core building on Office of Personnel Management evaluation competencies, and 2) a diversity, equity, and inclusion initiative with local universities to create a workforce development pipeline. Our workforce development core will design, deliver, and evaluate a professional workforce development program that focuses on providing mentored VA, QUERI, QI, and evaluation experience to master’s level research staff; and recruit, retain, and mentor a range of diverse, master’s-level staff with on the job evaluation experience with incoming projects for the EPIC QUERI. Guided by the QUERI Implementation Roadmap and engaging closely with the Office of Mental Health and Suicide Prevention (OMHSP) and the Homeless Programs Office (HPO)/National Center on Homelessness among Veterans (NCHAV), our proposed evaluations will examine the data to knowledge (pre-implementation), knowledge to performance (implementation), and performance to data (sustainment) capacity of Public Law 116-171, Section 201 Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program and the HPO iPad and iPhone outreach to homeless Veterans during COVID-19. Each evaluation’s specific learning agenda and evaluation question will be unique; however, our overall specific aims are as follows: Aim 1: Identify pre- implementation barriers to adopting evidence-based practices (EBPs), policies, and implementation strategies across VA; Aim 2: Evaluate the implementation of EBPs, policies, and implementation strategies; and Aim 3: Ensure sustainment of our EBPs and policies through ongoing program planning and stakeholder engagement with operational partners. Each evaluation begins with a logic model, incorporating RE-AIM and Proctor’s Implementation Outcomes Framework. Our Methods Core consists of SMEs in health system engineering, quality improvement, implementation science, policy analysis, demography, health economics, psychometrics and survey design, and rapid ethnographic and qualitative analysis. Primary outcomes will focus on pre- implementation (acceptability, appropriateness, feasibility), implementation (reach, effectiveness, adoption, and implementation metrics, such as number of facilities where implementation occurred, number of staff trained and Veterans served, and implementation strategies used, as identified in the QUERI ACTION Framework), and sustainment (maintenance metrics). These outcomes will assist VA leadership in understanding the value of implementation and quality improvement investments to inform program and policy decisions.", "keywords": [ "Address", "Adopted", "Adoption", "Area", "Attention", "Budgets", "COVID-19", "Caring", "Cellular Phone", "Communities", "Competence", "Consultations", "Data", "Demography", "Effectiveness", "Electronic Health Record", "Engineering", "Ensure", "Ethnography", "Evaluation", "Evidence based practice", "Federal Government", "Foundations", "Foxes", "Funding", "Government", "Government Agencies", "Grant", "Health Services Accessibility", "Health system", "Healthcare", "Homelessness", "Informatics", "Investments", "Knowledge", "Laws", "Leadership", "Learning", "Logic", "Maintenance", "Mental Health", "Mentors", "Methodology", "Methods", "Modeling", "Modernization", "Occupations", "Office Management", "Outcome", "Performance", "Personnel Management", "Policies", "Policy Analysis", "Proctor framework", "Program Development", "Program Evaluation", "Psychometrics", "Qi", "Quality of life", "Randomized", "Reach Effectiveness Adoption Implementation and Maintenance", "Research", "Research Personnel", "Science", "Suicide prevention", "Surveys", "Training", "Trust", "United States Department of Veterans Affairs", "Universities", "Veterans", "Veterans Health Administration", "Workforce Development", "comparison group", "data to knowledge", "design", "diversity and equity", "evidence base", "experience", "health economics", "implementation barriers", "implementation evaluation", "implementation outcomes", "implementation science", "implementation strategy", "insight", "knowledge translation", "operation", "outreach", "patient safety", "primary outcome", "programs", "recruit", "resilience", "response", "social health determinants", "telehealth", "virtual healthcare" ], "approved": true } }, { "type": "Grant", "id": "9665", "attributes": { "award_id": "272201700014C-P00018-9999-2", "title": "COVID-19: NIAID Regulatory Support Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-04-15", "end_date": "2023-04-14", "award_amount": 5253282, "principal_investigator": { "id": 25151, "first_name": "ASIMAH", "last_name": "RAFI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1608, "ror": "", "name": "TECHNICAL RESOURCES INTERNATIONAL, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1608, "ror": "", "name": "TECHNICAL RESOURCES INTERNATIONAL, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of this contract is to provide regulatory expertise and support to operate and manage the NIAID Regulatory Support Center (RSC) to provide a wide range of clinical research activities and programs for NIAID. The RSC provides comprehensive regulatory support to: 1) perform NIAID-funded and NIAID-sponsored domestic and international clinical trial research; 2) provide training in key functions of clinical trial research to NIAID staff, investigators, and collaborators; and 3) maintain all contract-associated data and records in the NIAID-Clinical Research Management System (N-CRMS), including the electronic submission of required regulatory information. This project will provide regulatory support services for the COVID-19 clinical trial ACTIV-2 (Outpatient Monoclonal Antibodies And Other Therapies).", "keywords": [ "Agreement", "COVID-19", "Clinical Research", "Clinical Trials", "Contracts", "Data", "Funding", "International", "Investigational New Drug Application", "Monoclonal Antibodies", "National Institute of Allergy and Infectious Disease", "Outpatients", "Preparation", "Protocols documentation", "Records", "Research", "Research Activity", "Research Personnel", "Review Committee", "Services", "System", "Training", "clinical application", "human subject protection", "meetings", "programs" ], "approved": true } }, { "type": "Grant", "id": "9666", "attributes": { "award_id": "1I50HX003614-01", "title": "The Center for Policy Evaluation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-04-01", "end_date": "2027-03-31", "award_amount": null, "principal_investigator": { "id": 25486, "first_name": "David Chimin", "last_name": "Chan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25487, "first_name": "Anita A", "last_name": "Vashi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25488, "first_name": "TODD H", "last_name": "WAGNER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1497, "ror": "", "name": "VETERANS ADMIN PALO ALTO HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Center for Policy Evaluation (CPE) will conduct rigorous evaluations supporting the implementation of evidence-based policies and programs in the US Department of Veterans Affairs (VA). We will work with operational partners to conduct evaluations, using both existing administrative data and prospective designs, to provide insights into causal mechanisms. CPE will be organized around 3 core aims (Methods Core, Learning and Translation Core, Operations Core). The Center’s goals are rooted in the belief that VA is a learning health care system. Creating a learning health care system requires objective assessments that provide insights into causal mechanisms and local context. Sometimes operational leaders want answers to questions for which neither a randomized control trial nor a natural experiment can be found. These situations require innovative thinking about study design and expert judgment about the pros and cons of alternative methods. CPE investigators have significant experience in these skills; we have a history of being highly collaborative and innovative in combining qualitative and quantitative methods across a wide range of VA priority areas. CPE represents 30 investigators with expertise in community care, access, virtual care, long term, home-based and palliative care, disparities and social determinants of health (SDoH), delayed care from COVID, suicide and mental health, women's health, employment and health, burnout and staffing, exposures during deployment and spinal cord injuries, homelessness, EHR modernization, primary care, and complex patients. In year 1, we have proposed two evaluations and building a core data resource. The first evaluation examines the link between VBA disability benefits and mental health. This project will provide VA with evidence to guide VBA and VHA policy when it comes to benefits and mental health. This project will be led by Dr. Kritee Gujral with assistance from Drs. Liam Rose and Todd Wagner. The operational partners include OMHSP, ORH and OEI. The second evaluation examines Health Connect, a modernization of the Clinical Contact Centers, to streamline access to care and maximize first- contact resolution. This evaluation will assess the effectiveness of the Health Connect program in improving Veteran access to timely, quality care compared to care as usual prior to implementation. This project will help VA improve access and encourage greater reliance on VA for services. Drs. Diem Tran, Liam Rose, Jaqueline Ferguson, and Anita Vashi will lead this project from CPE. The primary partner is IVC and a secondary partner is the OCC. In year one we will also create core data resources to improve the quality and speed of subsequent evaluations. CPE has a long history of working with VA operational partners including the Office of Integrated Veterans Care, Office of Mental Health and Suicide Prevention, Office of Connected Care, and Office of Primary Care, just to name a few. CPE will be led by Todd Wagner, PhD, David Chan, MD, PhD, and Anita Vashi, MD, MHS, multiple PIs with Dr. Wagner serving as the corresponding PI. Drs. Wagner, Chan and Vashi are all investigators at the Palo Alto Center for Innovation to Implementation (Ci2i). The leadership team has unparalleled experience in conducting rigorous health services and health economic research with VA operational groups. Supporting the leadership team are 27 other VA investigators with diverse content expertise and strong connections across a range of departments and centers at Stanford University.", "keywords": [ "Address", "Area", "Belief", "Caring", "Clinical", "Communication", "Communities", "Complex", "Data", "Decision Making", "Doctor of Philosophy", "Economics", "Emergency Medicine", "Employment", "Ensure", "Environment", "Ethics", "Evaluation", "Funding", "Future", "Goals", "Health", "Health Services", "Health Services Accessibility", "Healthcare Systems", "Home", "Homelessness", "Improve Access", "Judgment", "Knowledge", "Lead", "Leadership", "Learning", "Link", "Mental Health", "Methodology", "Methods", "Military Personnel", "Mission", "Modernization", "Names", "Natural experiment", "Outcome", "Palliative Care", "Patients", "Physicians", "Plant Roots", "Policies", "Policy Making", "Primary Health Care", "Quality of Care", "Randomized Controlled Trials", "Recording of previous events", "Research", "Research Design", "Research Personnel", "Research Project Grants", "Resolution", "Resources", "Science", "Services", "Source", "Speed", "Spinal cord injury", "Suicide", "Suicide prevention", "Thinking", "Time", "Translating", "Translations", "United States Department of Veterans Affairs", "Universities", "Veterans", "Veterans Health Administration", "Voice", "Women&apos", "s Health", "Work", "base", "burnout", "connected care", "coronavirus disease", "cost", "data resource", "design", "disability", "dissemination strategy", "effectiveness evaluation", "evidence base", "experience", "health economics", "implementation science", "implementation strategy", "improved", "innovation", "insight", "interest", "operation", "programs", "prospective", "sexual trauma", "skills", "social health determinants", "tool", "treatment effect", "virtual healthcare" ], "approved": true } }, { "type": "Grant", "id": "9672", "attributes": { "award_id": "75N91019D00022-0-759102200001-1", "title": "BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-06-15", "end_date": "2023-12-14", "award_amount": 614163, "principal_investigator": { "id": 25494, "first_name": "MARGIE", "last_name": "CLAPPER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 750, "ror": "", "name": "RESEARCH INST OF FOX CHASE CAN CTR", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While the five-year survival rate for localized CRC is excellent at 90%, more than half of new CRC cases have the disease spread to regional lymph nodes and/or distant organs at the time of diagnosis. CRC with distant metastasis has a dismal five-year survival rate of 14.7%. These data clearly indicate that CRC-related mortality can be significantly improved if the disease is detected early and proper interventions could be deployed. Because CRC typically originates from precancerous colorectal polyps, routine colonoscopy screening provides an excellent opportunity to detect precursor or early lesions and reduce CRC-related morbidity and mortality. Indeed, the US Preventive Services Task Force recently updated its recommendation on CRC screening, noting the evidence that the screening in average-risk asymptomatic adults aged 50 to 75 years is of substantial benefit. Risk factors for CRC include age (>50), race (African American), obesity, cigarette smoking, type II diabetes, history of inflammatory bowel diseases, family history of colorectal polyps or CRC, and inherited genetic syndromes known to increase the CRC risks, such as familial adenomatous polyposis (FAP) and Lynch syndrome. FAP and Lynch syndrome are caused by germline mutations in the APC gene and DNA mismatch repair genes, respectively. The management of individuals with hereditary gastrointestinal cancer syndromes requires additional measures beyond what is recommended for the average-risk population to minimize the overall risk of cancer-associated morbidity and mortality. Management options for the confirmed mutation carriers include multiple aggressive screening, chemopreventive strategies, and prophylactic surgery. However, these interventions are associated with various degrees of adverse effects. Safer and more effective preventive measures are urgently needed for the individuals with FAP, Lynch syndrome, and other hereditary gastrointestinal cancer syndromes. Fusobacteria are common human oral gram-negative anaerobic microflora isolated from dental plaque and gum diseases, but rarely detectable in the colorectum of healthy individuals. In recent years, the enrichment of a specific pathotype, Fusobacterium nucleatum (Fn), has been demonstrated in the colonic tissues and stools from patients with colorectal adenomas and CRC. Clinical evidence suggests that the prevalence of Fn progressively increases from dysplasia, adenomas to CRC and the higher amount of Fn is significantly associated with CRC with high microsatellite instability, which is caused by DNA MMR deficiencies as seen in Lynch syndrome-associated CRC. The potential association of Fn with CRC tumorigenesis has been examined in a mouse model of FAP. ApcMin/+ mice, which carry a nonsense mutation at codon 850 of the Apc gene, had a significantly accelerated onset and increased multiplicity of both small intestinal and colorectal tumors after oral inoculation of Fn. These data strongly suggested the tumor-promoting role of Fn in ApcMin/+ mice. Interestingly, Fn did not induce colitis in these animals, in contrast to enterotoxigenic Bacteroides fragilis, which has been shown to cause colitis and accelerate tumorigenesis in ApcMin/+ mice. It has also been demonstrated that Fn promotes CRC, breast, and cervical cancer metastasis and can metastasizes with tumor cells. Although how Fn contributes to CRC tumorigenesis has yet to be fully elucidated, emerging evidence points to its virulence factors, such as FadA and Fap2, as potential enhancers of CRC tumorigenesis and progression. The Fap2 has been shown to bind to human T-cell immunoglobulin ITIM domain (TIGIT), an immunoglobulin superfamily receptor known to function as an immune co-inhibitory molecule. Fap2-binding to TIGIT on NK and other T cells protects tumor cells from NK cell-mediated cytotoxicity and blocks effector T cell functions in the tumor microenvironment. TIGIT has also been shown to promote Treg function. Taken together, Fn may exert tumor promoting effects not only by promoting CRC tumor growth, but also by exploiting the immune-suppressive function of TIGIT via its virulence factor protein and contributing to tumor immune evasion mechanisms. Cancers caused by infectious agents are theoretically preventable, if one can prevent the infection, eradicate oncogenic pathogens before tumor development, or suppress the functions of oncogenic molecules. Prophylactic vaccines for human papillomavirus and hepatitis B virus have been associated with significant reductions in infection rates, which are expected to result in the dramatic decrease in the incidence of cervical cancers and hepatocellular carcinoma, respectively. Compared to the prevention of infection, the eradication of oncogenic infectious agents already colonized in the host is in general highly challenging, if not impossible. For example, the well-established eradication regimens for Helicobacter pylori, which increases the risk of noncardia gastric cancers, do not eradicate the bacteria in all cases. Rather, emerging resistance to multiple antibiotics appears to be contributing to the recent decline in the eradication rate. Alternatively, the host immune defense system may be fortified by pathogen-targeted vaccines, if they can boost anti-pathogen immunity and lead to the containment of infection or suppression of pathogen-mediated tumorigenic functions. Fn is a gram-negative anaerobic bacillus, and can be isolated from 60-70% of children aged 5-7 years. As with other gram-negative bacteria, Fn produces outer membrane vesicles (OMVs), which contain much of the biological content of the Fn, but without replicative capacity and some of the soluble proteins found in OMVs may elicit anti-Fn immunity. As part of the PREVENT project to develop Fn OMV based anti-Fn vaccine (https://reporter.nih.gov/project-details/9358850), the proteomic characterization of Fn OMV led to the identification of putative immunogenic components, some of which may be useful as anti-Fn vaccine antigens. Lipid nanoparticle (LNP)-encapsulated mRNA vaccines against COVID-19 revolutionized the implementation of mRNA-based vaccinology. In addition to modifications of mRNA such as with pseudouridine incorporation to reduce innate immune responses and mRNA purification methodologies to remove contaminants, the development of biocompatible LNPs significantly boosted the advancement of COVID and other mRNA-based vaccines. LNP-RNA vaccine platform offers several advantages over conventional protein-based vaccination, including a rapid development, refined adjustment of antigenic epitopes, easier scale-up and timely deployment. The the current study aims to develop and evaluate the immunogenicity of soluble protein-based and LNP-RNA-based Fn vaccines and to determine anti-Fn activity and immunopreventive efficacy of Fn-associated CRC, using mouse models of FAP and Lynch syndrome.", "keywords": [ "APC gene", "Adult", "Adverse effects", "Advisory Committees", "African American", "Age", "American", "Anaerobic Bacteria", "Animals", "Antibiotics", "Antigens", "ApcMin/+ mice", "Bacillus", "Bacteria", "Bacteroides fragilis", "Binding", "Biological", "COVID-19", "Cancer Etiology", "Cell physiology", "Cell-Mediated Cytolysis", "Chemopreventive Agent", "Child", "Clinical", "Codon Nucleotides", "Colitis", "Colonoscopy", "Colorectal", "Colorectal Adenoma", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Polyp", "Containment", "DNA", "Data", "Dental Plaque", "Development", "Diagnosis", "Disease", "Distant", "Distant Metastasis", "Dysplasia", "Encapsulated", "Enhancers", "Epitopes", "Familial Adenomatous Polyposis Syndrome", "Family history of", "Feces", "Fusobacteria", "Fusobacterium nucleatum", "Genetic", "Germ-Line Mutation", "Goals", "Gram-Negative Bacteria", "Helicobacter pylori", "Hepatitis B Virus", "Hereditary Nonpolyposis Colorectal Neoplasms", "Human", "Human Papilloma Virus Vaccine", "ITIM", "Immune", "Immune Sera", "Immunity", "Immunoglobulins", "Immunosuppression", "Incidence", "Individual", "Infection", "Infection prevention", "Infectious Agent", "Inflammatory Bowel Diseases", "Inherited", "Innate Immune Response", "Intervention", "Lead", "Lesion", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Malignant neoplasm of gastrointestinal tract", "Measures", "Mediating", "Membrane", "Messenger RNA", "Methodology", "Microsatellite Instability", "Mismatch Repair", "Mismatch Repair Deficiency", "Modeling", "Modification", "Morbidity - disease rate", "Natural Killer Cells", "Neoplasm Metastasis", "Non-Insulin-Dependent Diabetes Mellitus", "Nonsense Mutation", "Obesity", "Oncogenic", "Operative Surgical Procedures", "Oral", "Organ", "Patients", "Phase", "Population", "Preclinical Drug Development", "Prevalence", "Preventive", "Preventive measure", "Preventive service", "Preventive vaccine", "Primary carcinoma of the liver cells", "Program Development", "Proteins", "Proteomics", "Pseudouridine", "RNA", "RNA vaccine", "Race", "Recommendation", "Recording of previous events", "Regimen", "Regulatory T-Lymphocyte", "Reporter", "Resistance", "Risk", "Risk Factors", "Role", "Small Intestinal Neoplasm", "Survival Rate", "Syndrome", "System", "T-Lymphocyte", "Time", "Tissues", "Tumor Escape", "United States", "United States National Library of Med" ], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1424, "count": 14236 } } }